Portfolio company
Lyell Immunopharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies and solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Leucid Bio
This biotechnology company develops chimeric antigen receptor T-cell therapies to treat patients with solid tumours and haematological malignancies.
Verismo Therapeutics
This company develops chimeric antigen receptor therapies for patients with solid tumours and B-cell lymphomas.
LYEL
This company develops engineered cell therapies to treat patients with solid tumours and blood cancers.
Caribou Biosciences
This biopharmaceutical company develops genome-edited allogeneic cell therapies to treat patients with hematologic malignancies and other human diseases.
curocell
This company develops chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory blood cancers such as diffuse large B-cell lymphoma.
PACT Pharma
This biopharmaceutical company develops personalised and off-the-shelf gene-engineered T-cell therapies to treat patients with solid tumours.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
CARGO Therapeutics
This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.